Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
Halberd (OTC PINK: HALB) has released the results of its WatchDawg® Pilot Study for PTSD treatment. The study involved 10 military veterans who received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies. Participants wore wrist monitors and used mobile phones to upload vital sign data to Athena GTX's FDA-cleared Device Management Suite.
The study revealed consistent positive impact of the treatment, with data indicating improved overall health. Monitored indicators included heart rate, blood oxygen level, respiration rate, and skin temperature. Dr. Mark Darrah, CEO of Athena GTX, stated that the results were very encouraging and met all objectives. The company plans to proceed to a 100-patient Phase 1 clinical trial, incorporating feedback to improve the treatment protocol.
Halberd (OTC PINK: HALB) ha pubblicato i risultati del suo studio pilota WatchDawg® per il trattamento del PTSD. Lo studio ha coinvolto 10 veterani militari che hanno ricevuto farmaci (LDX) e nutraceutici, insieme all'accesso 24 ore su 24 a terapie per la salute mentale. I partecipanti indossavano monitor al polso e utilizzavano telefoni cellulari per caricare i dati sui segni vitali nella Suite di Gestione Dispositivi approvata dalla FDA di Athena GTX.
Lo studio ha rivelato un impatto positivo costante del trattamento, con dati che indicano un miglioramento della salute complessiva. Gli indicatori monitorati includevano la frequenza cardiaca, il livello di ossigeno nel sangue, la frequenza respiratoria e la temperatura della pelle. Il Dr. Mark Darrah, CEO di Athena GTX, ha dichiarato che i risultati erano molto incoraggianti e hanno soddisfatto tutti gli obiettivi. L'azienda prevede di procedere a un trial clinico di Fase 1 con 100 pazienti, incorporando feedback per migliorare il protocollo di trattamento.
Halberd (OTC PINK: HALB) ha publicado los resultados de su estudio piloto WatchDawg® para el tratamiento del PTSD. El estudio involucró a 10 veteranos militares que recibieron farmacéuticos (LDX) y nutracéuticos, junto con acceso 24/7 a terapias de salud mental. Los participantes llevaban monitores en la muñeca y utilizaban teléfonos móviles para cargar datos de signos vitales en la Suite de Gestión de Dispositivos aprobada por la FDA de Athena GTX.
El estudio reveló un impacto positivo constante del tratamiento, con datos que indican una mejora en la salud general. Los indicadores monitoreados incluían la frecuencia cardíaca, el nivel de oxígeno en sangre, la tasa de respiración y la temperatura de la piel. El Dr. Mark Darrah, CEO de Athena GTX, declaró que los resultados eran muy alentadores y cumplían con todos los objetivos. La empresa planea pasar a un ensayo clínico de Fase 1 con 100 pacientes, incorporando comentarios para mejorar el protocolo de tratamiento.
Halberd (OTC PINK: HALB)는 PTSD 치료를 위한 WatchDawg® 파일럿 연구 결과를 발표했습니다. 이 연구에는 약물(LDX)과 건강보조식품을 받은 10명의 군인 재향군인들이 참여했으며, 24시간 정신 건강 치료를 받을 수 있었습니다. 참가자들은 손목 모니터를 착용하고 휴대폰을 사용해 Athena GTX의 FDA 승인 기기 관리 시스템에 생체 신호 데이터를 업로드했습니다.
연구 결과 지속적인 긍정적 영향이 나타났으며, 데이터는 전반적인 건강 개선을 보여주었습니다. 모니터링된 지표에는 심박수, 혈중 산소 수준, 호흡수, 피부 온도가 포함되었습니다. Athena GTX의 CEO인 마크 다라(Mark Darrah) 박사는 결과가 매우 고무적이며 모든 목표를 달성했다는 점을 강조했습니다. 회사는 100명 환자를 대상으로 한 1단계 임상시험으로 진행할 계획이며, 피드백을 반영하여 치료 프로토콜을 개선할 것입니다.
Halberd (OTC PINK: HALB) a publié les résultats de son étude pilote WatchDawg® pour le traitement du PTSD. L'étude a inclus 10 vétérans militaires qui ont reçu des médicaments (LDX) et des nutraceutiques, ainsi qu'un accès 24h/24 et 7j/7 à des thérapies de santé mentale. Les participants portaient des moniteurs au poignet et utilisaient des téléphones portables pour télécharger des données sur les signes vitaux dans la Suite de Gestion de Dispositifs d'Athena GTX, approuvée par la FDA.
L'étude a révélé un impact positif constant du traitement, avec des données indiquant une amélioration de la santé globale. Les indicateurs surveillés comprenaient la fréquence cardiaque, le niveau d'oxygène dans le sang, le taux de respiration et la température de la peau. Dr. Mark Darrah, PDG d'Athena GTX, a déclaré que les résultats étaient très encourageants et ont atteint tous les objectifs. L'entreprise prévoit de passer à un essai clinique de Phase 1 avec 100 patients, en intégrant les retours pour améliorer le protocole de traitement.
Halberd (OTC PINK: HALB) hat die Ergebnisse seiner WatchDawg® Pilotsstudie zur PTSD-Behandlung veröffentlicht. An der Studie nahmen 10 Militärveteranen teil, die Pharmazeutika (LDX) sowie Nutraceuticals erhielten, und Zugriff auf 24/7-Mentaltherapien hatten. Die Teilnehmer trugen Handgelenkmonitore und verwendeten Mobiltelefone, um Vitalzeichen-Daten in die von der FDA zugelassene Device Management Suite von Athena GTX hochzuladen.
Die Studie zeigte einen konstant positiven Einfluss der Behandlung, wobei die Daten auf eine Verbesserung der allgemeinen Gesundheit hinweisen. Überwachungsindikatoren umfassten die Herzfrequenz, den Blutoxygenwert, die Atemfrequenz und die Hauttemperatur. Dr. Mark Darrah, CEO von Athena GTX, erklärte, dass die Ergebnisse sehr ermutigend waren und alle Ziele erreicht wurden. Das Unternehmen plant, zu einer Phase-1-Studie mit 100 Patienten überzugehen und dabei Feedback zur Verbesserung des Behandlungsprotokolls zu integrieren.
- Pilot study showed consistent positive impact on participants' health
- Successfully met all objectives set for the pilot study
- Planning to proceed to a larger 100-patient Phase 1 clinical trial
- Proprietary LDX/CBN combination and specialized yoga/meditation positively impacted health and wellness
- Effective data acquisition system supported participants throughout the study
- None.
Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System
JACKSON CENTER, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation. Participants wore a wrist monitor and used a mobile phone to upload vital sign data to the FDA-cleared Athena Device Management Suite (ADMS). Participant data was analyzed pre- and post-therapy. The study revealed consistent positive impact of the treatment with data indicating improved overall health.
During the study, various indicators of wellbeing were monitored in each participant via wearable technology developed by AthenaGTX, including, heart rate, blood oxygen level, respiration rate and skin temperature. Participants received troubleshooting support and participated in weekly Zoom calls with a physician to discuss system issues, problems, and anecdotal evidence. The program's details, objectives, and market summary were outlined in a prior press releases here and here.
Dr. Mark Darrah, CEO of Athena GTX, stated, “The results of this Pilot Study are very encouraging. We met all of our objectives set for this effort, helped the participants with improved health, and discovered ways we can improve the treatment methodology going forward. The proprietary LDX/CBN combination and specialized yoga/meditation positively impacted health and wellness, and the data acquisition system effectively supported participants. We will use what we learned plus feedback from participants to improve the treatment protocol as we proceed to a 100-patient Phase 1 clinical trial.”
Dr. Darrah continued, “As we enter the next programmed step, we wanted to remind any interested parties to consider enrolling in or supporting Phase 1 trials. This is an open invitation to witness first-hand the value and ease of the therapy and its impact.”
William A. Hartman, President and CEO of Halberd Corporation, added, “The results thus far indicate the treatment methodology is having very promising results in the long-term care and treatment of patients suffering from PTSD and associated physical health issues. We remain hopeful that this will result in a widely accepted standard of care.”
Note: The full Athena GTX WatchDawg press release can be accessed via this link.
To get the latest on Halberd’s exciting developments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/).
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC
About Athena GTX, Inc.
Athena GTX is a certified DoD small business with Corporate Headquarters in Johnston, Iowa. Athena focuses development on wearables and highly mobile, wirelessly connected monitoring technologies, and transitioning those to key markets to meet unmet needs of first responders worldwide. Wireless Patient Monitoring – Athena GTX connects patient and provider About - Athena GTX® Inc.
About Halberd Corporation.
Halberd Corporation (OTC PINK: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners. Halberd’s policy for responding to individual shareholder questions is to be responsive, while refraining from providing information which relates to or could compromise any information pertaining to trade secrets or that may otherwise compromise our competitive advantages. Simultaneously with such disclosure or potential disclosure, Halberd will make the responsive information public through a tweet, press release or some other form of social media/mass media communication.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
(C) 2024, Halberd Corporation
FAQ
What were the results of Halberd 's WatchDawg® PTSD treatment pilot study?
How many participants were involved in Halberd's PTSD treatment pilot study?
What is the next step for Halberd 's PTSD treatment program?
What technology was used to monitor participants in Halberd's PTSD treatment study?
